Verismo Therapeutics, a company co-founded by Michael C. Milone, MD, PhD, an associate professor of Pathology and Laboratory Medicine, and Donald Siegel, PhD, MD, a professor of Pathology and Laboratory Medicine, has raised $16 million in equity financing, reported the Philadelphia Business Journal. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma and ovarian cancer.
Read PBJ article
Company website